Skip to main content

Table 2 Nuclear staining of enadenotucirev in patients with CRC (IT injection vs IV infusion)

From: Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

Cohort Patient Total number of sections Nuclear staining (%)
0 > 0 ≤ 20 > 20 ≤ 40 > 40 ≤ 60 > 60 ≤ 80 > 80 ≤ 100 No tumor
A (IT injection) IT0201 42 0 31 8 3 0 0 0
IT0203 14 0 0 0 2 11 1 0
IT0204 42 1 0 0 0 4 30 7
IT0301 21 7 14 0 0 0 0 0
IT0302 28 14 11 2 1 0 0 0
Total, n (%) 147 (100.0) 22 (15.0) 56 (38.1) 10 (6.8) 6 (4.1) 15 (10.2) 31 (21.1) 7 (4.8)
B (IV infusion) IV0101 49 0 38 8 3 0 0 0
IV0201a 21 0 0 3 0 11 7 0
IV0301 70 0 25 11 13 6 8 7
IV0302b 63 0 21 9 9 4 6 14
IV0303 21 0 11 7 3 0 0 0
Totalb, n (%) 224 (100.0) 0 (0.0) 95 (42.4) 38 (17.0) 28 (12.5) 21 (9.4) 21 (9.4) 21 (9.4)
  1. aPatient did not have surgery until 51 days after the first IV infusion of enadenotucirev
  2. bNumber corrected from data source